IMMUNE ALGORITHMICS
  • Home
  • Algocyte
  • Team
  • Science
  • Consulting
  • Contact
  • Blog
  • Webmail
  • MHS

Blog

OIA is accepted into the SpinLab's Prestigious Accelerating Programme

16/1/2021

 
Picture
SpinLab, one of the best-ranked accelerating programmes in Europe based in Leipzig, Germany, has selected OIA as one of its new handful healthcare startups out of hundreds of applications to be supported and introduced to partners in the areas of application of OIA's flagship product, Algocyte, including insurance companies and healthcare organisations.

SpinLab is a partner of the HHL Leipzig Graduate School of Management, one of Europe's most prestigious business schools, and works with a partner portfolio of over 25 corporations. This will open up OIA's network in Europe.

OIA's New Branch Office in Abu Dhabi, U.A.E.

28/11/2020

 
Supported by HUB71, a new subsidiary of OIA, Immune Algorithmics Middle East Ltd, has officially started operations and opened an office in Abu Dhabi. Soon, the first team will be landing in the new office seeking to raise funds and start commercial agreements in the region. OIA is planning to use its Middle East office to expand to the Middle and Far East.

Abu Dhabi and the United Arab Emirates are an international hub, technology magnet and an unmatched location for business in the region. The new office is located in the 16th floor of a building in a prime location at the Abu Dhabi Global Market Square (right picture above). The Abu Dhabi Global Market (ADGM) is an international financial centre located on Al Maryah Island in the United Arab Emirates's capital, Abu Dhabi.

OIA is accepted into the 'CDL-recovery' programme in Atlanta, U.S. to help the world bounce back

3/10/2020

 
Picture
OIA has been accepted into the 'CDL-recovery' programme in Atlanta, U.S. with the purpose to explore the U.S. market and contribute to the world recovery during and after COVID-19. Particularly chosen by the Creative Destruction Lab because of our solution's potential to contribute to the challenge of remote health monitoring, OIA and Algocyte are in a privileged position to help medical professionals and patients, specially those with conditions neglected because of the pandemic.

OIA chose Atlanta as its CDL affiliation to explore an incursion into the U.S. and North American markets from a world healthcare hub city. The Creative Destruction Lab (CDL) is a programme for massively scalable, science-based companies that pairs founders with experienced entrepreneurs and investors to set focused, measurable objectives with the goal of maximising equity-value creation. CDL was founded in 2012 in Toronto, Canada by Prof. Ajay Agrawal.

The impact of COVID19 on Patients with Chronic Diseases

29/9/2020

 
Most global healthcare resources are focused on COVID19 and this is largely disrupting the continuum of care for patients with chronic diseases (Chudasama et al., 2020). It has been reported that fear of contacting GPs during the COVID19 outbreak may be fuelling missed diagnoses (The Guardian, 2020). Results from a poll by NHS England, released in April, revealed that 40% of people said they were avoiding contacting their GP because of concerns about burdening the NHS (GPOnline, 2020).
“During a pandemic, other health conditions do not cease to exist, and we’ve seen from health crises in the past that there are sometimes more deaths from conditions unrelated to the pandemic than the virus causing the pandemic itself” 
Prof. Martin Marshall, the chair of the Royal College of GPs.
Many patients with chronic medical conditions or those undergoing diagnostic or therapeutic procedures require regular blood tests. This is currently performed at a hospital, clinic or GP's surgery, or in some cases through a visit by a phlebotomist or a district nurse to the patient’s home. Consequently, the requirement for self-isolation and social distancing during the pandemic has resulted in many patients being unable to receive an optimal level of monitoring. Even in non-pandemic times, the current system of contact-based blood testing is very inefficient and wasteful of precious NHS resources. There is consensus amongst healthcare providers that remote patient consultations could be very effective, and are very desirable, but are hampered by the need for contact-based blood testing (Royal College of Physicians, 2018).

There is also an additional, and more fundamental, problem with how we monitor patient blood results. Blood results are reported based on a binary category of normal or abnormal in comparison with population reference values. However, unsurprisingly, the population ‘normal’ ranges are generally very wide. A crude and simplistic binary categorisation of blood results often implies that even when a patient’s blood values move dramatically within the normal reference values, clinicians can dismiss this change if it remains within the range considered to be healthy. Unquestionably, however, significant rapid changes, for example in total White Blood Cell (WBC) count, are likely to have been precipitated by biologically and potentially medically-consequential causes which are currently ignored. There is now strong evidence that even when all other known factors are taken into consideration, changes in immune cell numbers such as WBC count are predictive of risk of disease and death, even in entirely healthy people (Shah et al., 2017; Alpert et al., 2019). In this context, personalised and longitudinal monitoring of a person’s immune system with a tool like Algocyte
®, has the potential to generate important insights into health and disease, particularly in the case of vulnerable patients.
Picture
Oxford Immune Algorithmics (OIA) aims to support the health care sector and the NHS with Algocyte®, a service that allows clinicians to remotely monitor their patients' health and immune systems through a Full Blood Count (and possible complementary blood tests). 

As part of OIA’s partnership with the NHS, OIA is currently offering service contracts to NHS organisations without charge in order to maximise the patient and societal benefits of this remote blood testing service and help with the increasing demand and accumulated backlog during the pandemic. To this end, we invite organisations to contact us with a description of how immune cell monitoring can help your patients. If appropriate, this service will be subsidised 100% by OIA. Currently, 
OIA is running pilots at Addenbrooke's Cambridge University Hospitals and  the Medici GP Practice (15,000 patients) in Luton.

Millions could be putting their long-term health at risk by not getting the proper monitoring that their conditions need (UniteLive, 2020) and we believe we are in a position to help.

Please contact us by completing the short form at the end of the page:


Complete the form
References:
​
  • Yogini V. Chudasama et al., Diabetes Metab Syndr, 2020.
  • Fear of contacting GPs during Covid outbreak 'fuelling missed diagnoses', The Guardian, September 23, 2020.
  • Millions of patients 'avoiding calls to GP' during COVID-19 pandemic By Nick Bostock, GP Online, April 2020.
  • Royal College of Physicians, Outpatients: The Future. Adding Value through Sustainability. 2018.
  • Shah et al, BMJ Open 2017.
  • Alpert et al, Nature Medicine 2019.
  • Millions waiting for tests as NHS backlog builds, UniteLive, Wednesday, 2020

Sinldo signs letter of intent to introduce Algocyte INto 400 medical units in china

21/9/2020

 
Picture
Sinldo Information Technology Co., Ltd. based in Beijing, is a leading Hospital Information Technology and mobile healthcare solution provider in China. It covers over 1,000 major public hospitals (400+ Grade A/Class A), 2000 community hospital and medical institutions, with over 600 million patient visits per year.

Sinldo has connected more than 1.5 million doctors and helps to manage 200 million patients each year. The letter of intent outlines the terms of conditions of a commercial agreement and involves the introduction and commercialisation of Algocyte in the regional hospital network in Shanxi province, An Kang city, Han Bin district, in China where there are 3 hospitals in the city, 36 community hospitals and 400 medical units in the surrounding villages which are connected by Sinldo’s digital platform that covers 1,020,000 people.

Signed by Dr Hongqiao Yang Sinldo, Chairman of Sinldo, the letter also establishes a further exploration of a wider adoption of Algocyte in hospital networks across China including 3000 regional hospitals and other medical units.

Why Use Algocyte?*

24/8/2020

 
We asked patients and doctors and this is what they said
Picture

Patients




Algocyte is helping change how frequent and where people are monitored and get tested but currently most people (89%) are still in high risk of infection by travelling to GP practices and hospitals to get their blood testing done, especially among those requiring regular monitoring (30%).
Picture
Patients found that getting a regular appointment for a blood test was too long (at least a week on average)
Picture
which together with the time they had to wait for their blood test results amounted to up to two more weeks in total.
Picture
A majority of patients say yes to finger-pricking over the alternatives
Picture
Patients find useful the main features of Algocyte.
Picture

Practitioners

The number of tests and hours that doctors and nurses request and spend on blood testing is significant
Doctors found that they spend several hours a week that could be rather spent on other activities and save appointment enabled by the responsible AI-powered capabilities of Algocyte, including providing more time and greater quality of care to patients.
Picture
Picture
There was a clear consensus on time-saving and usefulness of results and analytics in a remote app and solution for rapid remote blood testing.

* Data collected from a survey independently conducted and answered by 28 people including doctors (all levels), paramedics, nurses, and patients by the Medici Medical Centre clinic in Luton on June 11, 2020, a GP practice with over 15,000 patients.

OIA MEMBERS DELIVER invited talk on oia's cutting-edge A.I. at automata 2020

15/8/2020

 
OIA's CTO Dr. Jürgen Riedel and Senior AI Researcher Dr. Santiago Hernández-Orozco deliver a technical invited talk at the international conference AUTOMATA 2020, the 26th International Workshop on Cellular Automata and Discrete Complex Systems, one of the most reputable conferences in the field.

Jürgen and Santiago explained some of the most fundamental technical aspects behind OIA's A.I. and Machine Learning approaches to transform medicine from simple statistical pattern-matching to causal diagnostics and how OIA's methods and technology gives OIA an edge when it comes to robustness (e.g. to perturbations and interventions), generalisation (over-fitting avoidance) and explainability in what we call a responsible A.I. approach to applications in healthcare.

According to a survey from London venture capital firm MMC, 40% of European startups that are classified as A.I. companies don't actually use artificial intelligence in a way that is “material” to their businesses. Another percentage are startups or companies that adopt AI, but very few innovate in AI as much as in its domain of application like OIA does with its group of AI leaders and pioneers.

Here are some of OIA's most recent papers in some of the top journals in the fields of AI, automata and molecular biology research:
  • Rule Primality, Minimal Generating Sets and Turing-Universality in the Causal Decomposition of Elementary Cellular Automata
    Journal of Cellular Automata, vol. 13, pp. 479–497, 2018.
  • Causal Deconvolution by Algorithmic Generative Models
    ​Nature Machine Intelligence, vol 1, pages 58–66, 2019​.
  • Training-free Measures Based on Algorithmic Probability Identify High Nucleosome Occupancy in DNA Sequences
    Nucleic Acids Research, gkz750, 2019​.
  • An Algorithmic Information Calculus for Causal Discovery and Reprogramming Systems
    ​iScience, S2589-0042(19)30270-6, 2019​.
  • Algorithmic Probability-guided Machine Learning On Non-differentiable Spaces
    arXiv:1910.02758v2 Machine Learning (cs.LG), 2020. ​

OIA OPENS new office and lab in cambridge to serve the NHS Cambridge University Hospitals

4/7/2020

 
Found in a strategic location at the Sheraton House, Castle Park only a few minutes walking from the city centre of Cambridge, the new OIA office and lab will be OIA's second location joining our headquarters' office at Davidson House in Reading. OIA Cambridge will have the main purpose to support the haematology and oncology department at Addenbrooke's Hospital, one of the largest and most reputable hospitals and cancer research hubs in the UK and Europe with whom OIA has signed a collaboration and commercial agreement. With this office, OIA will be in a position to launch and extend a premium service covering most of the Golden Triangle.

OIA is a gold sponsor of automata 2020

4/7/2020

 
Picture
Oxford Immune Algorithmics is sponsoring the 26th International Workshop on Cellular Automata and Discrete Complex Systems AUTOMATA 2020. The conference aims to:

  • Establish and maintain a permanent, international, multidisciplinary forum for the collaboration of researchers in the field of Cellular Automata (CA) and Discrete Complex Systems (DCS).
  • Provide a platform for presenting and discussing new ideas and results.
  • Support the development of theory and applications of CA and DCS (e.g. parallel computing, physics, biology, social sciences, and others) as long as fundamental aspects and their relations are concerned.
  • Identify and study within an inter- and multidisciplinary context, the important fundamental aspects, concepts, notions and problems concerning CA and DCS.

AUTOMATA 2020 will focus on the theory and applications that many of OIA's own proprietary methods are based upon, in the deep connections of discrete dynamical systems complexity theory and algorithmic information. There will be special sessions and tutorials led by OIA's members on Automata in Machine Learning and on Algorithmic Information Dynamics with a particular interest in aspects of computability in causation, AI and reprogrammability. This shows again OIA's commitment to bridge industry and academia.

oia signs collaboration and commercial agreement with the nhs

15/6/2020

 
Picture
Picture
We are thrilled to announce that Oxford Immune Algorithmics signed last week a collaboration and commercial agreement with the National Health Service in the UK to serve and continue co-developing Algocyte® in Addenbrooke's Hospital at the Cambridge University Hospitals NHS Foundation Trust, one of the most important hospitals in the UK.

Algocyte
® will be deployed at the Department of Paediatric Haematology, Oncology and Palliative Care to help paediatric cancer patients to get supportive monitoring while preventing them to visit the hospital where they are exposed to greater risk of infection due to COVID-19.

​We want to thank partners, collaborators and investors that made this possible believing in us and supporting our project to help clinicians and these vulnerable patients.

OIA is nominated for the best Start-up medtech award 2020 by obn

15/6/2020

 
Picture
We are happy to announce that Oxford Immune Algorithmics has been nominated to the OBN awards for the Best Start-up Medtech in the UK. The awards celebrate outstanding achievement throughout the life sciences industry. 

OBN is the not-for-profit organisation supporting and bringing together the UK’s life sciences companies, corporate partners and investors. Their 400-plus Member companies are located across the Golden Triangle (Oxford, London and Cambridge) and beyond to Manchester, Nottingham, the Midlands, South Coast and Scotland.

​The nomination already feels like winning and we are very grateful to OBN for this prestigious nomination.

Oxford Immune Algorithmics is now a CogX 2020 Sponsor with a virtual booth

20/5/2020

 
OIA has become a sponsor and will join CogX 2020 as an exhibitor with a dedicated virtual booth. CogX is the Festival of AI and Emerging Technology and will take place on the 8th-10th June 2020. CogX has gone

Traditionally held in London, CogX 2020 is going Virtual and has become a  pop-up 3-day 36 channel online TV network with a Virtual Expo. They expect to beat their audience target and provide even greater connections to everyone involved. I hope you find you at our virtual booth at CogX 2020!

Our chief medical officer and coo explain the clinical need and demo algocyte (lancelot version)

14/5/2020

 

OXFORD IMMUNE ALGORITHMICS IS AWARDED A GRANT TO EXPLORE Applications of automata to areas of causation and machine intelligence

2/5/2020

 
OIA has been awarded a grant by recommendation of the Foundational Questions Institute & Fetzer Franklin Fund, a donor advised fund of the Silicon Valley Community Foundation. 

The FQXi catalyses, supports, and disseminates research on questions at the foundations of physics, particularly new frontiers and innovative ideas integral to a deep understanding of reality. 

The mission of the Fetzer Franklin Fund is to explore the frontiers of scientific knowledge and to advance breakthroughs towards scientific views of reality that are integrated and relational. the Fetzer Franklin Fund focuses on foundational questions at the frontiers of physics, biology, and consciousness research. The Fund supports work that re-examines the foundations of science, including scientific methodologies for both conventional and frontier research.

​The Silicon Valley Community Foundation
is the largest regional grant maker in the United States and was conceived to advance innovative philanthropic solutions to challenging problems, engaging donors to make the world a better place for all and 

OIA presenting its responsible ai technology at the Predictive analytics world summit

12/4/2020

 
Picture
Our CEO, Dr. Hector Zenil, will be delivering the opening Keynote at the Predictive Analytics World summit on May 11, 2020 originally planned to be held in Munich, Germany but now to be held online. He will be talking about Responsible AI in Health Care and Medicine, our research at the forefront of science at OIA and our approach with Algocyte®. Other speakers include Dr. Anna Bauer-Mehren, Head of Data Science at Roche; and Dr. Joran Lookerbol, Director of the Centre for Machine Learning at the Netherlands Institute of Mental Health.
Picture

OIA to make a major announcement at INTELLIGENT HEALTH INSPIRED

9/4/2020

 
Picture
We are sponsors, again, of the Intelligent Health summit where Dr. Kourosh Saeb-Parsy, OIA's Chief Medical Officer, will make a major announcement introducing Project Lancelot, OIA and Algocyte's response to Covid-19 (or its consequences) with our remote health monitoring cutting-edge technology for which OIA was created and we now finds itself in the middle of a pandemic being able to make an important contribution to the challenges posed by the crisis.
Pictures from the previous Intelligent Health summit earlier in 2020 at the ExCel conference centre in London (today, unfortunately, converted into the Nightingale's Hospital because of Covid-19, almost overnight becoming one of the largest hospitals in the world)

SFC and KIN CAPITAL JOIN OIA AS investors WITH JOINT FUNDS FROM THE BRITISH BUSINESS BANK

9/4/2020

 
Picture
We have successfully closed our latest funding round with SFC and KIN Capital leading it, award winning investors, both joining last week our multinational shareholder's board supporting OIA.

​This is a major milestone as other startups and companies find it increasingly difficult to find funding in a time of crisis. We are very proud to have SFC and KIN joining OIA's journey and for the trust placed on us by investors of this calibre, it feels very much like validation of what we have been doing in the last 1.5 years developing Algocyte
®.

We are thrilled that SFC and KIN have seen value in OIA even (or especially) in times like a pandemic. Their investment will help us respond to the increasing interest we are seeing in our services from the NHS. We will now start our next funding round and it is already looking very promising as we are in advanced talks with some of the largest and greatest VCs in the UK.

OIA invited to pitch ALGOCYTE® at STHLM TECH

5/4/2020

 
Picture
According to the organisers, STHLM TECH is the largest startup event in Europe where every geek, hacker, entrepreneur, investor, and designer around Stockholm comes together under one roof.
​

In this edition, there were 3 special guests announced, including leading investors from Canada and Holland. Omers is behind many of the top startups from Canada including Shopify, and DuckDuckGo. Originally planned to be held at the Hilton Slussen in Stockholm, the event was streamed live from live.sthlmtech.com on Monday 6 April, 2020.

Representing OIA was Dr. Kourosh Saeb-Parsy, our Chief Medical Officer, who gave a great pitch about Algocyte
® for which we received useful feedback from investors and organisers who were very optimistic about our approach and business model. 
There were around 140 attendants and more than 50 of them voted for the best company pitch:
Picture
OIA's Algocyte® pitch won by a large percentage (82%) against two other great startups, and we got very useful feedback from top investors.

OIA, ALGOCYTE & COVID-19

17/3/2020

 
Picture
Oxford Immune Algorithmics (OIA), like almost every other company and organisation around the world is putting in place contingency plans to downsize operations and send people home to work remotely while trying to be the least disruptive in the development and evolution of our products and goals.

We believe that the current situation is a challenge but also an opportunity. We believe that the current crisis will help humanity better rank priorities, realise that these events can happen and may become the norm if this new family of virus becomes seasonal with different degrees of disruption. We can acknowledge how unprepared was the world to face this challenge and how important would have been to have the means to monitor people's health remotely. Indeed, during a crisis like this one patients are asked to avoid coming to hospitals and surgeries even if they are seriously ill yet unable to get care because of risk of infection. This doesn't have to happen with Algocyte®.

OIA has been working on Algocyte® for almost 2 years and has now a full end-to-end CE Marked (under the CE Medical Device directive) app for remote blood testing and health monitoring that can help with these situations and may even save lives by enabling medical doctors to provide coverage without risk of infection for the health professional or the patient.

We are certain that OIA and Algocyte® will become thus even more relevant because we had our priorities right and we knew this was something the world requires to better handle medical emergencies and, in general, regular patient monitoring.

If our vision resonates with your and you believe that we can make a difference as a health or medical professional to your organisation or practice please contact us at changetheworld@immunealgorithmics.com

Oxford Immune Algorithmics is chosen as one of the 50 most promising game-changers in the Thames Valley in the UK

2/3/2020

 
Picture
Oxford Immune Algorithmics (OIA) has been chosen one of 50 game-changers in the Thames Valley (UK's Silicon Valley) for the creation of Algocyte and our responsible AI approaches awarded by ConnectTVT supported by Deloitte UK, Reading University's Henley Business School, BDB Pitmas and Austin Fraser.

The Thames Valley has the greatest concentration of IT companies in the UK covering the region to the West of London from Swindon to Slough including Oxford and Reading. Other companies with headquarters in Reading and the area include Microsoft, Oracle, Nvidia, DEC, HP, Vodafone, NaturalMotion, Nanopore, among many others.

OIA has been chosen for 'pushing the boundaries with innovation' for its Algocyte platform and solution, the accredited (CE as a medical device), most portable, and sophisticated remote blood testing solution for health monitoring available.

Representing OIA were Kim, Jürgen (CTO and co-founder) and Santiago.
Picture
Our Press Release is available here:
press_release02-02-2020.pdf
File Size: 322 kb
File Type: pdf
Download File

Distance and Colour-based Scores for Blood Test Risk Stratification

11/2/2020

 
We have published our first paper to introduce the novel numerical and colour-based risk stratification score available through our Algocyte® platform for remote blood testing and health monitoring. We think this score can be adopted as a medical standard so we made available the full description of how it was designed and implemented in Algocyte®. The score quantifies abnormality in blood test values, it indicates how removed values of an individual are from considered healthy reference values from the literature or derived from empirical data such as medical surveys as we did from the CDC NHANES database.

​The scores' behaviour can be adjusted to incorporate medical knowledge by assigning multipliers or 'weights' to individual components and is rooted on a numerical and a colour-based scheme. We test the score against real and synthetic data from medically relevant cases, extremes cases, and empirical blood cell count data from the CDC NHANES survey spanning 13 years, from 2003 to 2016. We find that both the numerical and colour-based scores are informative in distinguishing healthy individuals from those with diseases manifested with abnormal blood results.

Picture

Picture
 http://dx.doi.org/10.1101/2020.02.09.941096. 

SUCCESSFUL RELEASE PRESENTATION OF ALGOCYTE VERSION 1 AT INTELLIGENT HEALTH 2020 UK IN LONDON

8/2/2020

 
With over 1000 attendants at London's largest event venue, the Excel, the sold-out Intelligent Health 2020 event was a success and OIA/Algocyte was one of the featured sponsors where we introduced and promoted our remote blood testing and health monitoring innovative solution. 
Attending from OIA were Ago Forcella (COO), Ed Sant'Anna (Chief Strategist), Steeve Tchatchuing and Ines Amri (Business Associates).

OXFORD IMMUNE ALGORITHMICS Partners with the University of Reading to support their local internship scheme

25/1/2020

 
Oxford Immune Algorithmics (OIA) is very proud to have partnered with the University of Reading and welcomes two of their students in Computer Science hired with the partial support of the University of Reading internship scheme and grant. OIA is engaged with the local community and the young people of Reading where OIA's headquarters are located. 
Picture

ALGOCYTE® ACHIEVES CE CERTIFICATION AS A MEDICAL DEVICE

15/1/2020

 
We are very excited to share the announcement that we have accomplished a major milestone getting Algocyte® certified under the European Commission medical device directive. Algocyte® is OIA's flagship product, an end-to-end app and solution for remote blood testing and health monitoring based on our proprietary technology (two patents pending no. 1918950.5 and 1918948.9 (UK)).
Picture
Picture

OIA SPONSORS & EXHIBITS AT INTELLIGENT HEALTH UK IN LONDON

15/1/2020

 
OIA will be exhibiting at one of the world’s leading summits on AI in medicine, Intelligent Health 2020 on 5 February 2020 at a prime venue, the ExCel, London, U.K. where we will be promoting Algocyte, our flagship product for end-to-end remote blood testing and health monitoring.
Picture
Picture
<<Previous

    Archives

    January 2021
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    May 2019
    April 2019
    March 2019
    January 2019

    RSS Feed

Picture
Picture
A 50 game-changers company

Copyright © 2020
​Oxford Immune Algorithmics
Privacy Policy
Terms and Conditions
  • Home
  • Algocyte
  • Team
  • Science
  • Consulting
  • Contact
  • Blog
  • Webmail
  • MHS